OpenAIRE is about to release its new face with lots of new content and services.
During September, you may notice downtime in services, while some functionalities (e.g. user registration, login, validation, claiming) will be temporarily disabled.
We apologize for the inconvenience, please stay tuned!
For further information please contact helpdesk[at]openaire.eu

fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Halliday, Alice; Turner, Joseph D.; Guimarães, Ana; Bates, Paul A.; Taylor, Mark J. (2016)
Publisher: BioMed Central
Journal: Parasites & Vectors
Languages: English
Types: Article
Subjects: qx_70, Leishmania, Infectious Diseases, qv_771, Research, qv_4, qv_38, Lymphatic filariasis, wc_880, Vaccine, Lipopeptide, Adjuvant, Toll-like receptor, Parasitology
Background\ud Toll-like receptors (TLRs) play an important role in the innate and adaptive immune responses to pathogens, and are the target of new vaccine adjuvants. TLR2 plays a role in parasite recognition and activation of immune responses during cutaneous leishmaniasis infection, suggesting that TLR2 could be targeted by adjuvants for use in Leishmania vaccines. We therefore explored using Pam2CSK4 (Pam2) and Pam3CSK4 (Pam3) lipopeptide adjuvants, which activate TLR2/6 and TLR2/1 heterodimers respectively, in vaccine models for parasitic infections.\ud \ud \ud Methods\ud The use of lipopeptide adjuvants was explored using two vaccine models. For cutaneous leishmaniasis, the lipopeptide adjuvants Pam2 and Pam3 were compared to that of the Th1-driving double-stranded DNA TLR9 agonist CpG for their ability to improve the efficacy of the autoclaved Leishmania major (ALM) vaccine to protect against L. major infection. The ability of Pam2 to enhance the efficacy of a soluble Brugia malayi microfilariae extract (BmMfE) vaccine to protect against filarial infection was also assessed in a peritoneal infection model of B. malayi filariasis. Parasite antigen-specific cellular and humoral immune responses were assessed post-challenge.\ud \ud \ud Results\ud The use of lipopeptides in ALM-containing vaccines did not provide any protection upon infection with L. major, and Pam2 exacerbated the disease severity in vaccinated mice post-challenge. Pam2, and to a lesser extent Pam3, were able to elevate antigen-specific immune responses post-challenge in this model, but these responses displayed a skewed Th2 phenotype as characterised by elevated levels of IgG1. In the B. malayi vaccine model, the use of Pam2 as an adjuvant with BmMfE induced significant protective immunity to the same level as inclusion of an Alum adjuvant. Here, both Pam2 and Alum were found to enhance antigen-specific antibody production post-challenge, and Pam2 significantly elevated levels of antigen-specific IL-4, IL-5 and IL-13 produced by splenocytes.\ud \ud Conclusions\ud These data indicate that TLR2/6-targeting ligands could be considered as adjuvants for vaccines that require robust Th2 and/or antibody-dependent immunity.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Duthie MS et al. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev. 2011;239(1):178-96.
    • 2. Didierlaurent AM et al. AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity. J Immunol. 2009;183(10):6186-97.
    • 3. Maisonneuve C et al. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci U S A. 2014;111(34):12294-9.
    • 4. Raman VS, et al. Adjuvants for Leishmania vaccines: From Models to Clinical Application. Front Immunol. 2012;3:144:1-15.
    • 5. Llanos-Cuentas A et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine. 2010;28(46):7427-35.
    • 6. Reed SG, Coler RN, Campos-Neto A. Development of a leishmaniasis vaccine: the importance of MPL. Expert Rev Vaccines. 2003;2(2):239-52.
    • 7. Rhee EG et al. Vaccination with Heat-killed Leishmania Antigen or Recombinant Leishmanial Protein and CpG Oligodeoxynucleotides Induces Long-Term Memory CD4 + and CD8 + T Cell Responses and Protection Against Leishmania major Infection. J Exp Med. 2002;195(12):1565-73.
    • 8. Peters NC et al. Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice. J Immunol. 2012;189(10):4832-41.
    • 9. Becker I et al. Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. Mol Biochem Parasitol. 2003;130(2):65-74.
    • 10. Kavoosi G, Ardestani SK, Kariminia A. The involvement of TLR2 in cytokine and reactive oxygen species (ROS) production by PBMCs in response to Leishmania major phosphoglycans (PGs). Parasitology. 2009;136(10):1193-9.
    • 11. Vargas-Inchaustegui DA et al. Distinct Roles for MyD88 and Toll-Like Receptor 2 during Leishmania braziliensis Infection in Mice. Infect Immun. 2009;77(7):2948-56.
    • 12. Walker PS et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci U S A. 1999;96(12):6970-5.
    • 13. Hernández MX et al. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40. Immunol Lett. 2006; 105(1):38-47.
    • 14. Peters NC, et al. Evaluation of Recombinant Leishmania Polyprotein Plus Glucopyranosyl Lipid A Stable Emulsion Vaccines against Sand FlyTransmitted Leishmania major in C57BL/6 Mice. J Immunol. 2012;189(10): 4832-41.
    • 15. Okwor I, Kuriakose S, Uzonna J. Repeated inoculation of killed Leishmania major induces durable immune response that protects mice against virulent challenge. Vaccine. 2010;28(33):5451-7.
    • 16. Turner JD et al. A Randomized, Double‐Blind Clinical Trial of a 3‐Week Course of Doxycycline plus Albendazole and Ivermectin for the Treatment of Wuchereria bancrofti Infection. Clin Infect Dis. 2006;42(8):1081-9.
    • 17. Turner JD et al. Wolbachia Lipoprotein Stimulates Innate and Adaptive Immunity through Toll-like Receptors 2 and 6 to Induce Disease Manifestations of Filariasis. J Biol Chem. 2009;284(33):22364-78.
    • 18. Babayan SA, Allen JE, Taylor DW. Future prospects and challenges of vaccines against filariasis. Parasite Immunol. 2012;34(5):243-53.
    • 19. Babayan SA et al. Vaccination against filarial nematodes with irradiated larvae provides long-term protection against the third larval stage but not against subsequent life cycle stages. Int J Parasitol. 2006;36(8):903-14.
    • 20. Rajan TV et al. Brugian infections in the peritoneal cavities of laboratory mice: kinetics of infection and cellular responses. Exp Parasitol. 2002;100(4): 235-47.
    • 21. Paciorkowski N, Shultz LD, Rajan TV. Primed peritoneal B lymphocytes are sufficient to transfer protection against Brugia pahangi infection in mice. Infect Immun. 2003;71(3):1370-8.
    • 22. Martin C et al. IL-5 is essential for vaccine-induced protection and for resolution of primary infection in murine filariasis. Med Microbiol Immunol. 2000;189(2):67-74.
    • 23. Benmohamed L et al. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol. 1997;27(5):1242-53.
    • 24. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect Dis. 2002;2(7):425-31.
    • 25. Jackson DC et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A. 2004;101(43):15440-5.
    • 26. Bancroft AJ et al. The role of CD4 cells in protective immunity to Brugia pahangi. Parasite Immunol. 1994;16(7):385-7.
    • 27. Bates PA. Characterization of developmentally-regulated nucleases in promastigotes and amastigotes of Leishmania mexicana. FEMS Microbiol Lett. 1993;107(1):53-8.
    • 28. Griffiths KG et al. Using an intravenous catheter to carry out abdominal lavage in the gerbil. Lab Anim (NY). 2010;39(5):143-8.
    • 29. Bahar K et al. Comparative safety and immunogenicity trial of two killed Leishmania Major vaccines with or without BCG in human volunteers. Clin Dermatol. 1996;14(5):489-95.
    • 30. Turner JD et al. Wolbachia Endosymbiotic Bacteria of Brugia malayi Mediate Macrophage Tolerance to TLR- and CD40-Specific Stimuli in a MyD88/TLR2- Dependent Manner. J Immunol. 2006;177(2):1240-9.
    • 31. Finkelman FD et al. Lymphokine Control of in vivo Immunoglobulin Isotype Selection. Annu Rev Immunol. 1990;8(1):303-33.
    • 32. Moyle PM, Toth I. Self-adjuvanting lipopeptide vaccines. Curr Med Chem. 2008;15(5):506-16.
    • 33. Zaman M, Toth I. Immunostimulation by synthetic lipopeptide based vaccine candidates: structureactivity relationships. Front Immunol 2013;4: 318:1-12.
    • 34. Chua BY et al. The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses. Immunol Cell Biol. 2014;92(4):377-83.
    • 35. Cote-Sierra J et al. Bacterial Lipoprotein-Based Vaccines Induce Tumor Necrosis Factor-Dependent Type 1 Protective Immunity against Leishmania major. Infect Immun. 2002;70(1):240-8.
    • 36. Miles SA et al. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med. 2005;201(5):747-54.
    • 37. Kima PE et al. Internalization of Leishmania mexicana Complex Amastigotes via the Fc Receptor Is Required to Sustain Infection in Murine Cutaneous Leishmaniasis. J Exp Med. 2000;191(6):1063-8.
    • 38. Thomas BN, Buxbaum LU. Fc{gamma}RIII Mediates Immunoglobulin G-Induced Interleukin-10 and Is Required for Chronic Leishmania mexicana Lesions. Infect Immun. 2008;76(2):623-31.
    • 39. Buxbaum LU, Scott P. Interleukin 10- and Fcγ Receptor-Deficient Mice Resolve Leishmania mexicana Lesions. Infect Immun. 2005;73(4):2101-8.
    • 40. Yamazaki S et al. TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS One. 2011;6(4):e18833.
    • 41. Zeng W et al. Highly Immunogenic and Totally Synthetic Lipopeptides as SelfAdjuvanting Immunocontraceptive Vaccines. J Immunol. 2002;169(9):4905-12.
    • 42. Hutchison S et al. Antigen depot is not required for alum adjuvanticity. FASEB J. 2012;26(3):1272-9.
    • 43. Gavin AL et al. Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor Signaling. Science. 2006;314(5807):1936-8.
    • 44. Buwitt-Beckmann U et al. TLR1- and TLR6-independent Recognition of Bacterial Lipopeptides. J Biol Chem. 2006;281(14):9049-57.
    • 45. Eisenbarth SC et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008; 453(7198):1122-6.
    • 46. Coffman RL, Sher A, Seder RA. Vaccine Adjuvants: Putting Innate Immunity to Work. Immunity. 2010;33(4):492-503.
    • 47. McKee AS, Munks MW, Marrack P. How Do Adjuvants Work? Important Considerations for New Generation Adjuvants. Immunity. 2007;27(5):687-90.
    • 48. Flach TL et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med. 2011;17(4):479-87.
    • 49. Gray CA, Lawrence RA. A role for antibody and Fc receptor in the clearance of Brugia malayi microfilariae. Eur J Immunol. 2002;32(4):1114-20.
    • 50. Martin C et al. B-cell deficiency suppresses vaccine-induced protection against murine filariasis but does not increase the recovery rate for primary infection. Infect Immun. 2001;69(11):7067-73.
    • 51. Sharmila S et al. Bacterial lipid modification enhances immunoprophylaxis of filarial abundant larval transcript-2 protein in Mastomys model. Parasite Immunol. 2013;35(7-8):201-13.
    • 52. Dillon S et al. A Toll-Like Receptor 2 Ligand Stimulates Th2 Responses In Vivo, via Induction of Extracellular Signal-Regulated Kinase MitogenActivated Protein Kinase and c-Fos in Dendritic Cells. J Immunol. 2004; 172(8):4733-43.
    • 53. Dillon S et al. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest. 2006;116(4):916-28.
    • 54. Gowthaman U et al. Promiscuous peptide of 16 kDa antigen linked to Pam2Cys protects against Mycobacterium tuberculosis by evoking enduring memory T-cell response. J Infect Dis. 2011;204(9):1328-38.
    • 55. Pandey SP et al. Pegylated Bisacycloxypropylcysteine, a Diacylated Lipopeptide Ligand of TLR6, Plays a Host-Protective Role against Experimental Leishmania major Infection. J Immunol. 2014;193(7):3632-43.
    • 56. Jayakumar A et al. TLR1/2 Activation during Heterologous Prime-Boost Vaccination (DNA-MVA) Enhances CD8+ T Cell Responses Providing Protection against Leishmania (Viannia). PLoS Negl Trop Dis. 2011;5(6):e1204.
    • 57. Awate S, Babiuk LA, and Mutwiri G. Mechanisms of action of adjuvants. Front Immunol 2013;4:114:1-10.
    • 58. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12(6):509-17.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok